Prevalence and clinical implications of atrial fibrillation in patients hospitalized due to COVID-19: Data from a registry in Poland

Background Atrial fibrillation (AF) is a common arrhythmia with increasing prevalence with respect to age and comorbidities. AF may influence the prognosis in patients hospitalized with Coronavirus disease 2019 (COVID-19). We aimed to assess the prevalence of AF among patients hospitalized due to COVID-19 and the association of AF and in-hospital anticoagulation treatment with prognosis. Methods and results We assessed the prevalence of AF among patients hospitalized due to COVID-19 and the association of AF and in-hospital anticoagulation treatment with prognosis. Data of all COVID-19 patients hospitalized in the University Hospital in Krakow, Poland, between March 2020 and April 2021, were analyzed. The following outcomes: short-term (30-days since hospital admission) and long-term (180-days after hospital discharge) mortality, major cardiovascular events (MACEs), pulmonary embolism, and need for red blood cells (RBCs) transfusion, as a surrogate for major bleeding events during hospital stay were assessed. Out of 4,998 hospitalized patients, 609 had AF (535 pre-existing and 74 de novo). Compared to those without AF, patients with AF were older and had more cardiovascular disorders. In adjusted analysis, AF was independently associated with an increased risk of short-term {p = 0.019, Hazard Ratio [(HR)] 1.236; 95% CI: 1.035–1.476} and long-term mortality (Log-rank p < 0.001) as compared to patients without AF. The use of novel oral anticoagulants (NOAC) in AF patients was associated with reduced short-term mortality (HR 0.14; 95% CI: 0.06–0.33, p < 0.001). Moreover, in AF patients, NOAC use was associated with a lower probability of MACEs (Odds Ratio 0.3; 95% CI: 0.10–0.89, p = 0.030) without increase of RBCs transfusion. Conclusions AF increases short- and long-term risk of death in patients hospitalized due to COVID-19. However, the use of NOACs in this group may profoundly improve prognosis.

[1]  S. Basili,et al.  Prevalence of new-onset atrial fibrillation in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis , 2022, Internal and Emergency Medicine.

[2]  C. Tudoran,et al.  Increased Susceptibility for Thromboembolic Events versus High Bleeding Risk Associated with COVID-19 , 2022, Microorganisms.

[3]  M. Małecki,et al.  Comparison between COVID-19 outcomes in the first three waves of pandemic: a reference hospital report. , 2022, Polish archives of internal medicine.

[4]  Hannah E Marsh,et al.  The Incidence of Venous Thromboembolism in Critically Ill Patients with SARS-CoV-2 Infection Compared with Critically Ill Influenza and Community-Acquired Pneumonia Patients: A Retrospective Chart Review , 2022, Medical sciences.

[5]  F. Skjøth,et al.  Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy , 2022, JAMA network open.

[6]  M. Link,et al.  New-Onset Atrial Fibrillation in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Registry , 2022, Circulation. Arrhythmia and electrophysiology.

[7]  Shaima Hussain Alnajjad,et al.  Implications for COVID-19 , 2022, International journal of health sciences.

[8]  P. Verhamme,et al.  Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing , 2022, Research and Practice in Thrombosis and Haemostasis.

[9]  F. Rutten,et al.  Sex- and age specific association of new-onset atrial fibrillation with in-hospital mortality in hospitalised COVID-19 patients , 2022, International Journal of Cardiology. Heart & Vasculature.

[10]  G. Hindricks,et al.  ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up , 2021, Cardiovascular research.

[11]  G. Hindricks,et al.  ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up , 2021, European heart journal.

[12]  T. Ortel,et al.  Anticoagulant Therapy in Patients Hospitalized With COVID-19. , 2021, JAMA internal medicine.

[13]  M. Yakar,et al.  New‐onset atrial fibrillation in critically ill patients with coronavirus disease 2019 (COVID‐19) , 2021, Journal of arrhythmia.

[14]  M. Jaguszewski,et al.  Pharmacotherapy of atrial fibrillation in COVID-19 patients , 2021, Cardiology journal.

[15]  C. Specchia,et al.  Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  G. Lip,et al.  Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis , 2021, Journal of clinical medicine.

[17]  J. Chi,et al.  Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta‐analysis , 2021, Thrombosis Journal.

[18]  W. Ageno,et al.  Protective effect of oral anticoagulant drugs in atrial fibrillation patients admitted for COVID-19: Results from the CORIST study , 2021, Thrombosis Research.

[19]  C. Szlejf,et al.  Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge , 2021, Respiratory Medicine.

[20]  K. Stolarz-Skrzypek,et al.  Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland. , 2021, Kardiologia polska.

[21]  M. Zuin,et al.  Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 Patients , 2021, Journal of Interventional Cardiac Electrophysiology.

[22]  Shrestha Ghosh,et al.  Anticoagulation in COVID-19: current concepts and controversies , 2021, Postgraduate Medical Journal.

[23]  S. Costanzo,et al.  Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis , 2021, Seminars in Thrombosis and Hemostasis.

[24]  O. Bayturan,et al.  CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients , 2021, Journal of Thrombosis and Thrombolysis.

[25]  Ying-Jia Xu,et al.  Atrial Arrhythmias in Patients with Severe COVID-19 , 2021, Cardiology research and practice.

[26]  Sergio Raposeiras-Roubín,et al.  Fibrilación auricular en pacientes con COVID-19. Utilidad de la puntuación CHA2DS2-VASc: un análisis del registro internacional HOPE COVID-19 , 2021, Revista Española de Cardiología.

[27]  C. Macaya,et al.  [Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry]. , 2021, Revista espanola de cardiologia.

[28]  N. Islam,et al.  Sixty-day consequences of COVID-19 in patients discharged from hospital: an electronic health records study , 2021, European journal of public health.

[29]  J. Halperin,et al.  Atrial Fibrillation in Patients Hospitalized With COVID-19 , 2021, JACC: Clinical Electrophysiology.

[30]  S. Woolf,et al.  COVID-19 as the Leading Cause of Death in the United States. , 2020, JAMA.

[31]  S. Iliceto,et al.  Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study , 2020, International Journal of Cardiology.

[32]  B. Clary,et al.  Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis , 2020, EClinicalMedicine.

[33]  R. Mostard,et al.  [Mortality and re-admission after hospitalization with COVID-19]. , 2020, Nederlands tijdschrift voor geneeskunde.

[34]  M. Metra,et al.  Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study , 2020, European journal of heart failure.

[35]  J. Z. Zamorano Gómez,et al.  New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis. , 2020, Cardiology journal.

[36]  K. Simon,et al.  Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. , 2020, Polish archives of internal medicine.

[37]  S. Iacopino,et al.  New-Onset Cardiac Arrhythmias During COVID-19 Hospitalization , 2020, Circulation. Arrhythmia and electrophysiology.

[38]  S. Markowitz,et al.  Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID‐19 , 2020, Journal of cardiovascular electrophysiology.

[39]  Moon-Woo Seong,et al.  Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea. , 2020, Annals of laboratory medicine.

[40]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[41]  Jiawei Fan,et al.  Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[42]  M. Metra,et al.  Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk? , 2020, European heart journal.

[43]  S. Solomon,et al.  COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease , 2020, European journal of heart failure.

[44]  C. Specchia,et al.  Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy , 2020, European heart journal.

[45]  F. Crea,et al.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options , 2020, Cardiovascular research.

[46]  K. Simon,et al.  Annex #1 as of 8 June 2020 to: Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. , 2020, Polish archives of internal medicine.

[47]  Yutao Guo,et al.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.

[48]  Ji-Guang Wang,et al.  Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 , 2020, Cardiovascular research.

[49]  Taek Soo Kim,et al.  Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea , 2020, Annals of laboratory medicine.

[50]  M. Pawłowska,et al.  Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists. , 2020, Polish archives of internal medicine.

[51]  G. Fonarow,et al.  Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. , 2020, JAMA cardiology.

[52]  J. Kim,et al.  Risk Factor and Mortality in Patients with Pulmonary Embolism Combined with Infectious Disease , 2020, Tuberculosis and respiratory diseases.

[53]  D. McManus,et al.  Rates of Potentially Inappropriate Dosing of Direct‐Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE‐AF Study , 2020, Journal of the American Heart Association.

[54]  P. Hsu,et al.  A Population-Based Propensity Score-Matched Study to Assess the Impact of Repeated Vaccination on Vaccine Effectiveness for Influenza-Associated Hospitalization Among the Elderly , 2020, Clinical interventions in aging.

[55]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[56]  L. Køber,et al.  One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study. , 2019, European heart journal.

[57]  G. Tse,et al.  Atrial fibrillation is related to lower incidence of deep venous thrombosis in patients with pulmonary embolism. , 2018, Journal of thoracic disease.

[58]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[59]  A. Banerjee,et al.  Are Cardiovascular Risk Factors also Associated with the Incidence of Atrial Fibrillation? , 2017, Thrombosis and Haemostasis.

[60]  T. van der Poll,et al.  Incidence, Predictors, and Outcomes of New‐Onset Atrial Fibrillation in Critically Ill Patients with Sepsis. A Cohort Study , 2017, American journal of respiratory and critical care medicine.

[61]  Qixing Zhou,et al.  Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study , 2016, Journal of Thrombosis and Thrombolysis.

[62]  E. Benjamin,et al.  Risk factors and outcomes associated with new-onset atrial fibrillation during acute respiratory distress syndrome. , 2015, Journal of critical care.

[63]  E. Benjamin,et al.  Long-term outcomes following development of new-onset atrial fibrillation during sepsis. , 2014, Chest.

[64]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[65]  P. V. Rao,et al.  Applied Survival Analysis: Regression Modeling of Time to Event Data , 2000 .

[66]  OUP accepted manuscript , 2021, European Heart Journal.

[67]  Xianlong Zhang,et al.  A systematic review and updated meta-analysis , 2012 .

[68]  V. Preedy,et al.  Prospective Cohort Study , 2010 .